Literature DB >> 12556744

Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis.

Anthony J Comerota1.   

Abstract

Patients with iliofemoral deep venous thrombosis suffer the most severe postthrombotic morbidity. Techniques that effectively remove thrombus from the venous system eliminate venous obstruction and potentially preserve valvular function. This will likely reduce or avoid the postthrombotic syndrome and improve long-term quality of life. To evaluate whether catheter-directed thrombolysis is associated with improved quality of life compared with anticoagulation alone and whether outcome in the thrombolysis group is related to lytic success, 98 patients with iliofemoral deep venous thrombosis who were treated at least 6 months earlier were identified and queried with a validated health-related quality-of-life questionnaire. Sixty-eight patients were identified through the Venous Registry (a national, multicenter venous registry) and were treated with catheter-directed thrombolysis with urokinase, and 30 patients were identified by means of medical record review and were treated with anticoagulation alone. All patients were candidates for thrombolysis; however, the treatment decision was made according to physician preference. The two treatment groups did not differ significantly in average time between the reference hospitalization and first contact. No difference was found in physical functioning and well-being between the groups before the development of deep venous thrombosis. Following treatment, patients receiving catheter-directed thrombolysis reported better overall physical functioning, less stigma, less health distress, and fewer postthrombotic symptoms compared to those patients treated with anticoagulation alone. Within the thrombolysis group, successful lysis correlated with health-related quality of life. Catheter-directed thrombolysis for the management of patients with iliofemoral deep venous thrombosis significantly improves health-related quality of life compared to similar patients treated with anticoagulation alone. Improved quality of life is related to successful thrombolysis. These data offer a compelling argument for a prospective randomized study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12556744

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  6 in total

1.  EkoSonic Thrombolysis as a Therapeutic Adjunct in Venous Occlusive Disease.

Authors:  D S Zaghlool; R W Franz; J Jenkins
Journal:  Int J Angiol       Date:  2016-04-03

2.  Successful iliac vein and inferior vena cava stenting ameliorates venous claudication and improves venous outflow, calf muscle pump function, and clinical status in post-thrombotic syndrome.

Authors:  Konstantinos T Delis; Haraldur Bjarnason; Paul W Wennberg; Thom W Rooke; Peter Gloviczki
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

3.  Secondary Varicose Small Pelvic Veins and Their Treatment with Micronized Purified Flavonoid Fraction.

Authors:  Yurii T Tsukanov; Anton Y Tsukanov; Evgenii G Levdanskiy
Journal:  Int J Angiol       Date:  2015-12-31

4.  Temporary Vena Caval Interruption and Thrombolysis in the Management of Deep Vein Thrombosis.

Authors:  Gregg Elliott; Scott Stevens
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-06

5.  Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study.

Authors:  Tone Enden; Hilde Skuterud Wik; Ann Kristin Kvam; Ylva Haig; Nils Einar Kløw; Per Morten Sandset
Journal:  BMJ Open       Date:  2013-08-29       Impact factor: 2.692

6.  Effects of Arteriovenous Thrombolysis Combined with Mechanical Thrombectomy on Efficacy and Neurological Function of Acute Cerebral Infarct Patients.

Authors:  Tao Ding; Liwen Tang; Bohong Hu; Junxin Yuan; Xiangdong Li; Jun Wen
Journal:  Biomed Res Int       Date:  2020-10-09       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.